The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Key Points: Prescribing appropriately for age and cardiovascular risk is likely to result in minimal permanent toxicity-related dasatinib cessation. CML patients on dasatinib with pleural effusion are more likely to have achieved MR4.5 after 6-month therapy than those without effusion.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most potential side-effects of D can be avoided though intermittent administration and, generally, serious side effects of D reverse upon temporary discontinuation [62,63], increasing the value of the opportunity to administer D intermittently, yet still benefit from its senolytic effects.”
Citations
The citation lists are queued
They are fetched later and appear here then.
References 31 · Cited by 43
Research works printed but not linked: 1
- 1940, New Engl J Med, 222, 782
Metadata
- Authors
- Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., Fleming, S., McQuillan, A., Schwarer, A., Harrup, R., Holmes, A., Ratnasingam, S., Chan, K.-L., Hsu, W.-H., Ashraf, A., Putt, F., & Grigg, A.
- Affiliations
- Epworth Hospital (AU)
- Austin Hospital (AU)
- Baker Heart and Diabetes Institute (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- Gosford Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Monash Health (AU)
- The Alfred Hospital (AU)
- Hollywood Medical Centre, Perth, Australia;
- Box Hill Hospital (AU)
- Royal Hobart Hospital (AU)
- Canberra Hospital (AU)
- The Royal Melbourne Hospital (AU)
- St Vincent's Hospital Melbourne (AU)
- Royal Prince Alfred Hospital (AU)
- Calvary Mater Newcastle Hospital (AU)
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2017-05-15
- Volume
- 1
- Issue
- 13
- Pages
- 802-811
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC5727806
- OpenAlex
- W2615918143
- Cited by
- 43
- References
- 31
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 10 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 6
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, chronic myeloid leukemia, drug toxicity, pulmonary hypertension, pleural effusion, cytopenia, antiplatelet therapy, dose adjustment, treatment discontinuation, adverse event incidence, natural history (disease)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2016003889
- The paper
- Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., Fleming, S., McQuillan, A., Schwarer, A., Harrup, R., Holmes, A., Ratnasingam, S., Chan, K.-L., Hsu, W.-H., Ashraf, A., . . . Grigg, A. (2017). The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2016003889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.